ADOCIA a biotechnology company dedicated to protein delivery

  • Contact
  • Linkedin
  • Twitter
  • Youtube
  • RSS
  • LANGUAGES
    • English English
    • Français Français
  • Presentation
    • About Adocia
    • Founders
    • Management
    • Board of Directors
    • Team
    • Scientific Advisory Board
    • Symbol
  • Technology
    • BIOCHAPERONE®
    • Intellectual property
    • Publications
  • Products
    • Pipeline
    • BIOCHAPERONE® LISPRO
    • BIOCHAPERONE® COMBO
    • M1Pram
    • BIOCHAPERONE® GLUCAGON
    • BIOCHAPERONE® Gla GLP-1
    • BioChaperone® Glucagon GLP-1
    • Cell Therapy: AdoShell Islets
  • Partnering
    • Licensing Opportunities
    • Contact
  • Financials
    • Home Investors
    • Regulated Information
    • Documentation
    • Shareholders
    • Shareholders meeting
    • Governance
    • Investors Contact
  • Careers
    • Working at Adocia
    • HR Policy
    • Gender Equality index
    • Offers
  • News & Events
    • Press Releases
    • Upcoming Events

BioChaperone®, A versatile platform adapted to a wide range of proteins

Homines enim eruditos et sobrios ut infaustos et inutiles vitant, eo quoque accedente quod et nomenclatores adsueti haec et talia venditare.

To date, Adocia researchers have developed a portfolio of more than 300 BioChaperone® polymers, oligomers and small organic compounds. The main variations among BioChaperone® polymers are size, nature, and number of anionic and hydrophobic grafts. Thanks to this diversity, the BioChaperone® technology has already been applied to three main categories of proteins of different sizes and properties.

 

Insulins

Insulin, a key hormone in the treatment of diabetes, has been combined with BioChaperone® to enhance its pharmacokinetics and pharmacodynamics.

Adocia is currently developing 4 insulin-based products using BioChaperone®:

 

  • BioChaperone® Combo: A combination of prandial and basal insulin based on insulin glargine. BioChaperone technology makes it possible to mix both insulins by solubilizing insulin glargine at Neutral pH.
  • BioChaperone® Lispro. This ultra-rapid insulin, licensed to Eli Lilly since December 2014, is being developed with the goal of optimizing glucose levels during and after meals.
  • BioChaperone® Human Glucagon. Glucagon is another key metabolic hormone which role is schematically opposite to that of insulin. A healthy pancreas secretes both insulin and glucagon to keep blood glucose into a tight physiological range. However, human glucagon is a very unstable molecule and commercially available products may only be reconstituted ex temporane from a lyophilized powder. Using the BioChaperone® technology, Adocia aims to develop a stable aqueous solution of recombinant human glucagon, that may be used in varied settings, including the treatment of severe hypoglycaemia and the use in an artificial pancreas.
  • HinsBet®, a BioChaperone® fast-acting human insulin, accelerates the pharmacokinetic profile of human insulin, aiming to obtain comparable performances to an insulin analog.

 

 

Technology

  • BioChaperone®
  • Intellectual property
  • Publications

BIOCHAPERONE® TECHNOLOGY

  • “Physically glycosylating” proteins
  • A versatile platform

A la Une / Spotlight

  • 100 years ago, the first insulin injection saved Leonard Thompson

    This week, it has been 100 years since 14-year-...
  • Upcoming Investor Conferences – January 2022

    Dear investors, Adocia invites you to meet mana...

  • Home
  • Terms Of Use
  • Privacy Policy
  • Contact
ADOCIA a biotechnology company dedicated to protein delivery

Copyright ADOCIA © 2018

TOP